Table 1.
Clinical and molecular characteristics of patients included in this study.
| Cohort | CGGA-RNAseq | TCGA-RNAseq | GSE16011 |
|---|---|---|---|
| (n = 325) | (n = 1032) | (n = 276) | |
| Age, years | |||
| Mean (range) | 43 (8–81) | 50 (10–87) | 51 (14–81) |
| Sex | |||
| Female | 122 | 400 | 88 |
| Male | 203 | 562 | 180 |
| Unavailable | 0 | 70 | 8 |
| KPS | |||
| Mean (range) | – | 81 (20–100) | 81 (0–100) |
| Unavailable | 325 | 376 | 0 |
| Primary or recurrent | |||
| Primary glioma | 240 | 0 | 0 |
| Recurrent glioma | 61 | 0 | 0 |
| Secondary GBM | 34 | 0 | 0 |
| Unavailable | 0 | 1032 | 276 |
| WHO grade | |||
| Grade II | 109 | 216 | 24 |
| Grade III | 72 | 241 | 85 |
| Grade IV | 144 | 505 | 159 |
| Unavailable | 0 | 70 | 0 |
| Histology | |||
| Oligodendroglioma | 40 | 159 | 52 |
| Oligoastrocytoma | 73 | 109 | 28 |
| Astrocytoma | 68 | 151 | 29 |
| Glioblastoma | 144 | 562 | 159 |
| Normal brain | 0 | 0 | 8 |
| Unavailable | 0 | 51 | 0 |
| Molecular classification | |||
| LGG-Oligo | 45 | 234 | 0 |
| LGG-Astro | 87 | 107 | 0 |
| LGG, IDH-wildtype | 49 | 78 | 0 |
| GBM, IDH-mutant | 39 | 36 | 0 |
| GBM, IDH-wildtype | 105 | 526 | 0 |
| Unavailable | 0 | 51 | 276 |
| TCGA subtype | |||
| Neural | 81 | 76 | 0 |
| Proneural | 102 | 83 | 0 |
| Classical | 74 | 738 | 0 |
| Mesenchymal | 68 | 135 | 0 |
| Unavailable | 0 | 0 | 276 |
| IDH status | |||
| Mutant | 171 | 456 | 82 |
| Wild-type | 154 | 454 | 139 |
| Unavailable | 0 | 122 | 55 |
| 1p/19q status | |||
| Codel | 0 | 156 | 0 |
| Non-codel | 0 | 853 | 0 |
| Unavailable | 325 | 23 | 0 |
| Overall survival, days | |||
| Median | 770 | 353 | – |
| Survival status | |||
| Alive | 168 | 478 | – |
| Dead | 142 | 503 | – |
| Unavailable | 15 | 51 | 276 |